We analyzed two lung adenocarcinoma cell lines, A549 cells and SW1573, harboring KRAS mutation and both KRAS and PIK3CA mutations, respectively, and identified five potentially effective inhibitors (BMS-345541, Dactinomycin, Epirubicin, Irinotecan, and Topotecan) from the previously screened set of 76 LUAD cell growth inhibitors by using GDSC data. Here, KRAS is linked to lung adenocarcinoma.